| 前收市價 | 0.1500 |
| 開市 | 0.1000 |
| 買盤 | 0.0000 |
| 賣出價 | 0.2000 |
| 拍板 | 2.50 |
| 到期日 | 2024-06-21 |
| 今日波幅 | 0.1000 - 0.1500 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 179 |
ZacksAllogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
InvestorPlaceIf You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names
Penny stocks carry a great deal of risk. It’s why investors are often told to steer clear of them. Many penny stocks typically trade over the counter and rarely on a major exchange. And about 90% of them fail. It’s why we include a warning at the tail-end of the article, and why the U.S. SEC has issued warnings against them. While you may get lucky and uncover the next Apple (NASDAQ:AAPL) or Advanced Micro Devices (NASDAQ:AMD) in the bunch, you have to dig through a lot of garbage. That’s not to
ZacksAllogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.
